Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer
MetadataShow full item record
Pancreatic cancer has one of the worst prognoses among all cancers due to the late manifestation of identifiable symptoms and high resistance to chemo- and radiation therapies. In recent years, a cancer development phase termed epithelial-mesenchymal transition (EMT) has gained increasing research focus. The process is implicated in tumour metastasis, and emerging evidence suggests EMT also contributes or induces chemoresistance in several cancers. Nevertheless, the applicability of therapeutic targeting of EMT faces many challenges. In this mini-review, we summarise the evidence supporting the role of EMT in pancreatic cancer progression, focusing particularly on its association with chemoresistance.
Showing items related by title, author, creator and subject.
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study Global Burden of Disease Cancer CollaborationFitzmaurice, C.; Allen, C.; Barber, R.; Barregard, L.; Bhutta, Z.; Brenner, H.; Dicker, D.; Chimed-Orchir, O.; Dandona, R.; Dandona, L.; Fleming, T.; Forouzanfar, M.; Hancock, J.; Hay, R.; Hunter-Merrill, R.; Huynh, C.; Hosgood, H.; Johnson, C.; Jonas, J.; Khubchandani, J.; Kumar, G.; Kutz, M.; Lan, Q.; Larson, H.; Liang, X.; Lim, S.; Lopez, A.; MacIntyre, M.; Marczak, L.; Marquez, N.; Mokdad, A.; Pinho, C.; Pourmalek, F.; Salomon, J.; Sanabria, J.; Sandar, L.; Sartorius, B.; Schwartz, S.; Shackelford, K.; Shibuya, K.; Stanaway, J.; Steiner, C.; Sun, J.; Takahashi, K.; Vollset, S.; Vos, T.; Wagner, J.; Wang, H.; Westerman, R.; Zeeb, H.; Zoeckler, L.; Abd-Allah, F.; Ahmed, M.; Alabed, S.; Alam, N.; Aldhahri, S.; Alem, G.; Alemayohu, M.; Ali, R.; Al-Raddadi, R.; Amare, A.; Amoako, Y.; Artaman, A.; Asayesh, H.; Atnafu, N.; Awasthi, A.; Saleem, H.; Barac, A.; Bedi, N.; Bensenor, I.; Berhane, A.; Bernabé, E.; Betsu, B.; Binagwaho, A.; Boneya, D.; Campos-Nonato, I.; Castañeda-Orjuela, C.; Catalá-López, F.; Chiang, P.; Chibueze, C.; Chitheer, A.; Choi, J.; Cowie, B.; Damtew, S.; Das Neves, J.; Dey, S.; Dharmaratne, S.; Dhillon, P.; Ding, E.; Driscoll, T.; Ekwueme, D.; Endries, A.; Farvid, M.; Farzadfar, F.; Fernandes, J.; Miller, Ted (2017)Importance: Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning. Objective: To estimate mortality, incidence, years lived with disability ...
Towards understanding disparities in cancer outcomes for Aboriginal Australians: exploring Aboriginal perceptions and experiences of cancer in Western AustraliaShahid, Shaouli (2010)Cancer has become one of the major chronic diseases among Aboriginal and Torres Strait Islander people of Australia, and was declared a health priority in the National Aboriginal and Torres Strait Islander Health Strategy ...
Rates of colonoscopy in the 3 years prior to a diagnosis of colorectal cancer in Western Australia: assessment of risk factors for missed and interval cancers. Preliminary results from a population-based studySalama, M.; Harma, C.; Fritschi, Lin; Heyworth, J.; Raftopoulos, S.; Ee, H. (2014)Introduction and Aims: Colonoscopy is the gold standard for diagnosing colorectal cancer (CRC) however there is a miss rate for cancers of up to 7.9%, with significant variability in this figure from different populations ...